Skip to main content
. 2022 Feb 15;149(2):779–789. doi: 10.1007/s00432-021-03898-8

Fig. 1.

Fig. 1

Fig. 1

a Waterfall plot—best percent change from baseline in sum of target lesion diameters (efficacy evaluable population)*; b spider plot—percent change from baseline in sum of target lesion diameters over time (efficacy evaluable population)*; c swimmer plot—response pattern of each subject (efficacy evaluable population)*. *Only assessments prior to initial of a new anti-cancer therapy included in the analysis. CR complete response, PR partial response, SD stable disease, PD progressive disease